Axis Direct's research report on Biocon
Q2FY17 PAT (up 29% YoY) was 9% higher than our estimate due to higher other income. However, 11% YoY growth in revenue/EBITDA was 5% below estimates given muted growth in Biologics (9% YoY) and 14% YoY decline in India business. While EBITDA margin was flat YoY at 23%, margin (ex-Syngene) was at 17% (declined 180 bps YoY/ 400 bps QoQ). Biocon maintains to file four biosimilar products in FY17and R&D expense at ~12% of bio-pharma sales (10% in Q2/ 9% in H1).
We raise our FY17/18F estimates by 10%/6.6%, driven by higher interest income and TP by 20% to Rs 960 {rollforward to 22x Sep-18E EPS (vs.22x FY18E)+ R&D value to Rs 160}. While core earnings are likely to remain muted in next 12-18m assuming higher depreciation at Malaysia plant, we maintain HOLD on back of advancing biosimilar pipeline which is expected to start contributing from FY19.
For all recommendations, click here Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
